Sign inJoin waitlistJoin the waitlist

Adrienne Waks

Physician · Dana-Farber Cancer Institute

Credentials: · · · ·

History

Dana-Farber Cancer Institute
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2014–2017
Internal Medicine
Brigham and Women's Hospital
2011–2014
Harvard Medical School
2007–2011
Princeton University
2003–2007

Research

Breast Cancer Treatment: A Review
Review · JAMA · 2019 · First of 2 authors · 3,495 citations
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Nature Communications · 2017 · 843 citations
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Cancer Discovery · 2020 · 352 citations

Sara Tolaney
40 papers
Eric Winer
26 papers
Elizabeth Mittendorf
23 papers
IK
Ian Krop
17 papers
Ann Partridge
13 papers
Nancy Lin
13 papers
PT
Paolo Tarantino
12 papers
Tari King
11 papers
Nadine Tung
10 papers
NW
Nikhil Wagle
9 papers
Meredith Faggen
7 papers
AW
Antonio Wolff
6 papers

Clinical trials

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Principal investigator · Active not recruiting · Phase 2
Adrienne G. Waks
2023–2027
VS-6766+Abema+Fulv in Met HR+/HER- BC
Principal investigator · Recruiting · Phase 1, Phase 2
Adrienne G. Waks
2023–2028
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2021–2030
MARGetuximab Or Trastuzumab (MARGOT)
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2020–2027